RRoche will partner with Dicerna to develop and commercialize the Phase I chronic hepatitis B virus (HBV) candidate DCR-HBVS, as well as discover and develop additional HBV treatments, through a collaboration that could generate more than $1.67 billion for Dicerna. [KATERYNA KON/SCIENCE PHOTO LIBRARY / Getty Images]
Roche will partner with Dicerna to develop and commercialize its lead product, the Phase I chronic hepatitis B virus (HBV) candidate DCR-HBVS, as well as discover and develop additional HBV treatments, through a collaboration that could generate more than $1.67 billion for Dicerna . . .
